AU2018287316B2 - Plasminogen treatment of conditions associated with PAI-1 overexpression - Google Patents

Plasminogen treatment of conditions associated with PAI-1 overexpression Download PDF

Info

Publication number
AU2018287316B2
AU2018287316B2 AU2018287316A AU2018287316A AU2018287316B2 AU 2018287316 B2 AU2018287316 B2 AU 2018287316B2 AU 2018287316 A AU2018287316 A AU 2018287316A AU 2018287316 A AU2018287316 A AU 2018287316A AU 2018287316 B2 AU2018287316 B2 AU 2018287316B2
Authority
AU
Australia
Prior art keywords
plasminogen
disease
pal
subject
overexpression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018287316A
Other languages
English (en)
Other versions
AU2018287316A1 (en
Inventor
Lyne Gagnon
Brigitte Grouix
Pierre Laurin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometic Biotherapeutics Inc
Original Assignee
Prometic Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Inc filed Critical Prometic Biotherapeutics Inc
Publication of AU2018287316A1 publication Critical patent/AU2018287316A1/en
Application granted granted Critical
Publication of AU2018287316B2 publication Critical patent/AU2018287316B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018287316A 2017-06-23 2018-06-22 Plasminogen treatment of conditions associated with PAI-1 overexpression Active AU2018287316B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523901P 2017-06-23 2017-06-23
US62/523,901 2017-06-23
PCT/IB2018/000655 WO2018234861A1 (en) 2017-06-23 2018-06-22 PLASMINOGEN TREATMENT OF AFFECTIONS ASSOCIATED WITH OVEREXPRESSION OF PAI-1

Publications (2)

Publication Number Publication Date
AU2018287316A1 AU2018287316A1 (en) 2020-02-06
AU2018287316B2 true AU2018287316B2 (en) 2024-09-19

Family

ID=64737041

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018287316A Active AU2018287316B2 (en) 2017-06-23 2018-06-22 Plasminogen treatment of conditions associated with PAI-1 overexpression

Country Status (20)

Country Link
US (1) US11826404B2 (enExample)
EP (1) EP3641888B1 (enExample)
JP (1) JP2020524689A (enExample)
KR (1) KR20200019217A (enExample)
CN (1) CN110831668B (enExample)
AU (1) AU2018287316B2 (enExample)
BR (1) BR112019027229A2 (enExample)
CA (1) CA3068153A1 (enExample)
CL (1) CL2019003789A1 (enExample)
DK (1) DK3641888T3 (enExample)
ES (1) ES2965937T3 (enExample)
FI (1) FI3641888T3 (enExample)
IL (1) IL271470B2 (enExample)
MX (1) MX2019015741A (enExample)
MY (1) MY203136A (enExample)
RU (1) RU2020100080A (enExample)
SG (1) SG11201912813SA (enExample)
TW (1) TWI868051B (enExample)
WO (1) WO2018234861A1 (enExample)
ZA (1) ZA202000280B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
TWI750189B (zh) 2016-12-15 2021-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
TWI787732B (zh) * 2020-02-06 2022-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療多發性硬化症的方法和藥物
CN115666625A (zh) * 2020-03-24 2023-01-31 泰伦基国际有限公司 一种促进错误折叠蛋白及其聚集物降解的方法和药物
US20230173039A1 (en) * 2020-03-24 2023-06-08 Talengen International Limited Method and drug for treating alzheimer disease
KR20220158036A (ko) * 2020-03-24 2022-11-29 탈렌젠 인터내셔널 리미티드 파킨슨병의 치료 방법 및 약물
CN112174979B (zh) * 2020-10-27 2021-09-07 黑龙江中医药大学 一种治疗多囊卵巢综合征的药物及其制备方法
WO2026006092A1 (en) * 2024-06-24 2026-01-02 The Cleveland Clinic Foundation Enzyme encapsulated nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006120423A1 (en) * 2005-05-09 2006-11-16 Prometic Biosciences Ltd. Affinity adsorbents for plasminogen
WO2017081529A1 (en) * 2015-11-10 2017-05-18 Prometic Biotherapeutics, Ltd. Plasminogen dosage regimen for wound healing

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
WO2001058476A2 (en) * 2000-02-11 2001-08-16 The European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
CA2662101C (en) * 2006-08-28 2015-07-07 Omnio Healer Ab Candidates against infection
AU2007290882B2 (en) 2006-08-28 2013-02-21 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
BR112016002753A2 (pt) * 2013-08-13 2017-11-21 Sanofi Sa anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
JP7213552B2 (ja) * 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
CA3047170A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating drug-induced renal injury
JP7168990B2 (ja) * 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006120423A1 (en) * 2005-05-09 2006-11-16 Prometic Biosciences Ltd. Affinity adsorbents for plasminogen
WO2017081529A1 (en) * 2015-11-10 2017-05-18 Prometic Biotherapeutics, Ltd. Plasminogen dosage regimen for wound healing

Also Published As

Publication number Publication date
IL271470A (en) 2020-01-30
WO2018234861A1 (en) 2018-12-27
EP3641888A4 (en) 2021-03-10
AU2018287316A1 (en) 2020-02-06
DK3641888T3 (da) 2024-01-02
EP3641888B1 (en) 2023-10-11
NZ760921A (en) 2026-01-30
FI3641888T3 (fi) 2023-12-19
US11826404B2 (en) 2023-11-28
US20210330761A1 (en) 2021-10-28
CN110831668A (zh) 2020-02-21
KR20200019217A (ko) 2020-02-21
EP3641888A1 (en) 2020-04-29
ZA202000280B (en) 2021-08-25
CN110831668B (zh) 2024-04-12
MY203136A (en) 2024-06-10
TW201904990A (zh) 2019-02-01
IL271470B2 (en) 2025-07-01
CA3068153A1 (en) 2018-12-27
SG11201912813SA (en) 2020-01-30
IL271470B1 (en) 2025-03-01
RU2020100080A3 (enExample) 2021-11-02
RU2020100080A (ru) 2021-07-23
ES2965937T3 (es) 2024-04-17
MX2019015741A (es) 2020-11-11
JP2020524689A (ja) 2020-08-20
CL2019003789A1 (es) 2020-07-10
TWI868051B (zh) 2025-01-01
BR112019027229A2 (pt) 2020-07-07

Similar Documents

Publication Publication Date Title
US11826404B2 (en) Plasminogen treatment of conditions associated with PAI-1 overexpression
ES2263174T3 (es) Bikunina humana.
ES2676422T3 (es) Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel
Seyfried et al. A selective cysteine protease inhibitor is non-toxic and cerebroprotective in rats undergoing transient middle cerebral artery ischemia
PT1491208E (pt) Composições farmacêuticas contendo polipéptido líquidas estabilizadas
WO2015070619A1 (zh) 鸢尾素在制备预防心肌缺血再灌注损伤的药物中的应用
AU2011224341B2 (en) Modulating aquaporins with relaxin
CA3152346A1 (en) Methods of treatment for modifying hemodynamics
US20260041663A1 (en) Prevention of rosacea inflammation
Earle et al. Ubiquitin reduces fluid shifts after traumatic brain injury
US6773704B1 (en) Methods of treating vascular disease associated with cystatin C deficiency
EP4471154A1 (en) Use of kinin or derivative thereof in treating vci, psci, or csvd
WO1997035609A1 (en) Neovascularization inhibitor containing tissue factor pathway inhibitor
HK40029531B (en) Plasminogen treatment of conditions associated with pai-1 overexpression
HK40029531A (en) Plasminogen treatment of conditions associated with pai-1 overexpression
US20200000939A1 (en) Method for creating a renal injury model to screen molecules for the treatment of renal injury
Jitsuiki et al. A case of blue rubber bleb nevus syndrome with Kasabach-Merritt syndrome and heart failure
JP2002522396A (ja) 乾癬治療用プロテアーゼ阻害因子
JP6289511B2 (ja) 羊水塞栓の治療剤
WO2019048898A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
WO2022224249A1 (en) Procoagulant peptides and use thereof
Kim et al. Altered pharmacology in burned patients
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)